Results 181 to 190 of about 98,704 (296)
This study reveals that infections are highly prevalent in pediatric IEI patients after umbilical cord blood transplantation, with early‐stage infections and bloodstream infections strongly associated with poorer survival. These findings advocate for risk‐stratified surveillance and preemptive strategies in high‐risk subgroups.
Zhongling Wei +8 more
wiley +1 more source
Molecular mechanisms of Epstein-Barr Virus in the pathogenesis of lymphomas and new opportunities for precision medicine. [PDF]
Gao H +8 more
europepmc +1 more source
CMV and EBV targets recognized by tumor-infiltrating B lymphocytes in pancreatic cancer and brain tumors [PDF]
Qingda Meng +4 more
openalex +1 more source
This retrospective case series of acyclovir‐resistant HSV infection in pediatric patients undergoing allogeneic HSCT discusses the clinical course, associated complications, and treatment, including side effects. We propose the first algorithm for investigating and managing acyclovir‐resistant HSV infections in pediatric HSCT recipients, highlighting ...
Jenna Nunn +9 more
wiley +1 more source
Latent, Lytic, and Linked to Multiple Sclerosis-How EBV Drives Autoimmunity. [PDF]
Läderach F, Bremer E, Münz C.
europepmc +1 more source
In a national US kidney transplant cohort, posttransplant lymphoproliferative disorder risk varied dynamically by donor–recipient Epstein–Barr virus serostatus. Donor‐positive/recipient‐negative recipients had the highest sustained risk, while donor‐negative/recipient‐negative recipients faced previously under‐recognized early risk, with PTLD strongly ...
Christie Rampersad +2 more
wiley +1 more source
Fatal refractory chronic active Epstein-Barr virus infection with hemophagocytic lymphohistiocytosis and NK/T-cell lymphoma: a case report. [PDF]
Mielke N +3 more
europepmc +1 more source
ABSTRACT Introduction Studies evaluating the incidence of infections after belatacept as a substitute for calcineurin inhibitors (CNI) or antimetabolite in kidney transplant (KT) yielded conflicting results. We compared infectious outcomes after belatacept‐use to no belatacept‐use in KT recipients.
Hareesh Singam +5 more
wiley +1 more source

